FDA Approves Kala Pharmaceuticals' Eysuvis for Short-Term Treatment of Dry Eye Disease - Eyewire+

EyewireTV | 10.28.2020

Now Playing

Thumbnail for rrfijc

Introduction

Previous EyewireTV Episodes

05.13.2026

Eyewire TV May 13, 2026 thumbnail

Introduction

story 1 thumbnail

Future of Regenerative Medicine

story 2 thumbnail

Update on AI Use and Innovation

story 3 thumbnail

Next-Generation Therapies

05.06.2026

Eyewire TV May 6, 2026 thumbnail

Introduction

story 1 thumbnail

Bayer Expands Ophthalmology Pipeline with Acquisiton of Perfuse Therapeutics

story 2 thumbnail

Viridian Announces REVEAL-2 Phase 3 Data for TED Treatment Elegrobart

story 3 thumbnail

Steven Dell, MD, Discusses Impact of Declining Medicare Reimbursement

04.29.2026

Eyewire TV April 29, 2026 thumbnail

Introduction

story 1 429 thumbnail

Brent Saunders, Bausch + Lomb

story 2 429 thumbnail

Julie Brewer, Alcon

story 3 429 thumbnail

Mark Baum, Harrow

04.22.2026

Eyewire TV Apil 22, 2026 thumbnail

Introduction

story 1 thumbnail

Glaukos Launches Epioxa for Keratoconus; Secures J-Code

story 2 thumbnail

BVI Receives CE Mark for Virtuoso Phaco-Vitrectomy Surgical System

story 3 thumbnail

ASCRS Executive Director Recaps Annual Sightline Meeting